Characterization of Transthyretin Mutation G47V Associated with Hereditary Cardiac Amyloidosis.

IF 1.9 4区 医学 Q3 CARDIAC & CARDIOVASCULAR SYSTEMS
Cardiology Pub Date : 2024-01-01 Epub Date: 2024-03-04 DOI:10.1159/000538081
Xiaopeng He, Mengdie Wang, Jialu Sun, Zhengyang Yu, Xinyang Hu, Yu Liu, Xiaoping Lin
{"title":"Characterization of Transthyretin Mutation G47V Associated with Hereditary Cardiac Amyloidosis.","authors":"Xiaopeng He, Mengdie Wang, Jialu Sun, Zhengyang Yu, Xinyang Hu, Yu Liu, Xiaoping Lin","doi":"10.1159/000538081","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Amyloidosis caused by TTR mutations (ATTRv) is a rare inherited and autosomal dominant disease. More than 150 mutants of TTR have been reported, whereas some of them remain to be investigated.</p><p><strong>Methods: </strong>A 52-year-old male presented with heart failure and clinically diagnosed ATTR cardiac amyloidosis (ATTR-CA) was recruited. Whole-exome sequencing (WES) was performed. Biochemical and biophysical experiments characterized protein stability using urea-mediated tryptophan fluorescence. Drug response was analyzed by fibril formation assay. Finally, tetramer TTR concentration in patient's serum sample was measured by ultra-performance liquid chromatography (UPLC).</p><p><strong>Results: </strong>For the proband, WES revealed a mutation (c.200G&gt;T; p.Gly67Val and referred to as G47V) in TTR gene. Biochemical and biophysical kinetics study showed that the thermodynamic stability of G47V-TTR (Cm = 2.4 <sc>m</sc>) was significantly lower than that of WT-TTR (Cm = 3.4 <sc>m</sc>) and comparable to that of L55P-TTR (Cm = 2.3 <sc>m</sc>), an early age-of-onset mutation. G47V:WT-TTR heterozygous tetramer kinetic stability (t1/2 = 1.4 h) was further compromised compared to that of the homozygous G47V-TTR (t1/2 = 3.1 h). Among three small molecule stabilizers, AG10 exhibited the best inhibition of the fibrillation of G47V-TTR homozygous protein. Using a UPLC assay, nearly 40% of TTR in this patient was calculated to be non-tetrameric.</p><p><strong>Conclusion: </strong>In this work, we reported a patient presented early onset of clinically typical ATTR-CA due to G47V-TTR mutation. Our work for the first time not only characterized the biochemical properties of G47V-TTR mutation, but also provided hints for the pathogenicity of this mutation.</p>","PeriodicalId":9391,"journal":{"name":"Cardiology","volume":null,"pages":null},"PeriodicalIF":1.9000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11309070/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cardiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000538081","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/4 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"CARDIAC & CARDIOVASCULAR SYSTEMS","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Amyloidosis caused by TTR mutations (ATTRv) is a rare inherited and autosomal dominant disease. More than 150 mutants of TTR have been reported, whereas some of them remain to be investigated.

Methods: A 52-year-old male presented with heart failure and clinically diagnosed ATTR cardiac amyloidosis (ATTR-CA) was recruited. Whole-exome sequencing (WES) was performed. Biochemical and biophysical experiments characterized protein stability using urea-mediated tryptophan fluorescence. Drug response was analyzed by fibril formation assay. Finally, tetramer TTR concentration in patient's serum sample was measured by ultra-performance liquid chromatography (UPLC).

Results: For the proband, WES revealed a mutation (c.200G>T; p.Gly67Val and referred to as G47V) in TTR gene. Biochemical and biophysical kinetics study showed that the thermodynamic stability of G47V-TTR (Cm = 2.4 m) was significantly lower than that of WT-TTR (Cm = 3.4 m) and comparable to that of L55P-TTR (Cm = 2.3 m), an early age-of-onset mutation. G47V:WT-TTR heterozygous tetramer kinetic stability (t1/2 = 1.4 h) was further compromised compared to that of the homozygous G47V-TTR (t1/2 = 3.1 h). Among three small molecule stabilizers, AG10 exhibited the best inhibition of the fibrillation of G47V-TTR homozygous protein. Using a UPLC assay, nearly 40% of TTR in this patient was calculated to be non-tetrameric.

Conclusion: In this work, we reported a patient presented early onset of clinically typical ATTR-CA due to G47V-TTR mutation. Our work for the first time not only characterized the biochemical properties of G47V-TTR mutation, but also provided hints for the pathogenicity of this mutation.

与遗传性心脏淀粉样变性相关的转甲状腺素突变 G47V 的特征。
简介TTR突变引起的淀粉样变性病(ATTRv)是一种罕见的常染色体显性遗传病。目前已报道的TTR突变体超过150种,但其中一些突变体仍有待研究:方法:招募了一名患有心力衰竭并经临床诊断为 ATTR 心脏淀粉样变性(ATTR-CA)的 52 岁男性。进行了全外显子组测序(WES)。生化和生物物理实验利用尿素介导的色氨酸荧光鉴定了蛋白质的稳定性。通过纤维形成试验分析了药物反应。最后,通过超高效液相色谱法(UPLC)测量了患者血清样本中四聚体 TTR 的浓度:结果:原告的全外显子组测序结果显示,TTR基因存在突变(c.200G>T;p.Gly67Val,简称G47V)。生化和生物物理动力学研究表明,G47V-TTR 的热力学稳定性(Cm = 2.4 M)明显低于 WT-TTR(Cm = 3.4 M),与 L55P-TTR (Cm = 2.3 M)(一种早发突变)相当。G47V:WT-TTR 杂合四聚体的动力学稳定性(t1/2 = 1.4 小时)比同源 G47V-TTR 的动力学稳定性(t1/2 = 3.1 小时)更差。在三种小分子稳定剂中,AG10 对 G47V-TTR 同源蛋白质纤维化的抑制效果最好。通过超高效液相色谱分析,该患者体内近 40% 的 TTR 是非四聚体:在这项工作中,我们报告了一名因 G47V-TTR 基因突变而导致临床上典型的 ATTR-CM 早发患者。我们的工作不仅首次描述了 G47V-TTR 突变的生化特性,还为该突变的致病性提供了提示。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Cardiology
Cardiology 医学-心血管系统
CiteScore
3.40
自引率
5.30%
发文量
56
审稿时长
1.5 months
期刊介绍: ''Cardiology'' features first reports on original clinical, preclinical and fundamental research as well as ''Novel Insights from Clinical Experience'' and topical comprehensive reviews in selected areas of cardiovascular disease. ''Editorial Comments'' provide a critical but positive evaluation of a recent article. Papers not only describe but offer critical appraisals of new developments in non-invasive and invasive diagnostic methods and in pharmacologic, nutritional and mechanical/surgical therapies. Readers are thus kept informed of current strategies in the prevention, recognition and treatment of heart disease. Special sections in a variety of subspecialty areas reinforce the journal''s value as a complete record of recent progress for all cardiologists, internists, cardiac surgeons, clinical physiologists, pharmacologists and professionals in other areas of medicine interested in current activity in cardiovascular diseases.
文献相关原料
公司名称 产品信息 采购帮参考价格
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信